Cardiologyendovascular revascularisationpaclitaxel-coated devices
Paclitaxel-coated vs Uncoated Devices in Infrainguinal Revascularisation: Insights from the SWEDEPAD 2 Trial
By MedXY|Oct 8, 2025
The SWEDEPAD 2 trial reveals that paclitaxel-coated devices do not improve quality of life at 1 year and raise concerns about increased 5-year mortality in patients with intermittent claudication undergoing lower limb revascularisation.
